Amsurg Corp (NASDAQ:AMSG) Q3 2016 Earnings Conference Call - Final Transcript
Nov 01, 2016 • 05:00 pm ET
Good day, everyone, and welcome to AmSurg Corp's Third Quarter Conference Call. Today's call is being recorded and a replay will be available starting today through November 10, 2016. The number for the replay is 719-457-0820 and the code is 8888662.
At this time for opening remarks, I would like to turn the call over to Mr. Chris Holden, President and Chief Executive Officer. Please go ahead, sir.
Christopher A. Holden
All right, thank you, Noah. I want to welcome everyone to our results for the third quarter of 2016 on our investor call for AmSurg Corp. I also want to thank everyone who's joining via the webcast. As always, joining me on the call today, Claire Gulmi, our Executive Vice President and Chief Financial Officer; Robert Coward, President of our Sheridan Physician Services Division and also our Chief Development Officer; and Phillip Clendenin, President of our Ambulatory Services Division. And before we begin, I'm going to turn it over to Claire to review the Safe Harbor disclosure.
Claire M. Gulmi
Certain statements in the conference call constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management expectations and are based upon currently available information. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of AmSurg to differ materially from those that are expressed in or implied by the forward-looking statements.
To the extent any non-GAAP financial measure is discussed in today's call, you will also find a reconciliation of that measure to the most directly comparable financial measure calculated according to GAAP in today's news release, which is posted on the company's website. These factors are discussed in more detail in the company's reports that are filed with the SEC, including, without limitation, AMSURG's Annual Report on Form 10-K for the year ended December 31, 2015, and other filings. Copies of these filings are available from AmSurg upon request.
I'll now turn it back over to Chris for opening comments.
Christopher A. Holden
Thank you, Claire. Let me begin by saying that we're pleased to report that we're making great progress towards our transformational merger with Envision Healthcare. We have received the required regulatory approvals including those from the Federal Trade Commission and the Securities and Exchange Commission. The special meeting of our shareholders is now scheduled for November 28, and we do expect to close the merger by the end of 2016.
Over the past month you may have noticed that we announced our new board and also our C-suite executive team. We continue to refine our integration plan with the goal of blending the best talent and best practices from both organizations, and solidifying our pathway to the $35 million in cost synergies plan for 2017. The process has been collaborative and collegial since we began, and there's a remarkable positive enthusiasm and a culture of high energy, which is fueling what's an extraordinary amount of work that's going on behind the scenes as we prepare